West Pharmaceutical Services, Inc. WST
370.44
(3.16)
(0.85%)
as of 25 Sep
- Market cap
- $26.3B
- P/E
- 47.1×
Follow WST
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
West Pharmaceutical Services, Inc. (WST) Net income
West Pharmaceutical Services, Inc.'s net income for fiscal 2025 was $493.7M, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $564.9M. Over the past ten years it has ranged from $95.6M (fiscal 2015) to $661.8M (fiscal 2021); the current reading is higher than 73% of that period. West Pharmaceutical Services, Inc. ranks 8th of 55 Medical Instruments & Supplies companies by net income.
Net income, annual
Annual
| Period | Net income | Change |
|---|---|---|
| FY2025 | $493.7M | 0.20% |
| FY2024 | $492.7M | (16.97%) |
| FY2023 | $593.4M | 1.28% |
| FY2022 | $585.9M | (11.47%) |
| FY2021 | $661.8M | 91.16% |
| FY2020 | $346.2M | 43.24% |
| FY2019 | $241.7M | 16.82% |
| FY2018 | $206.9M | 37.29% |
| FY2017 | $150.7M | 4.94% |
| FY2016 | $143.6M | 50.21% |
Quarterly
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $154.0M | 10.95% |
| Mar 2026 | $138.8M | 5.07% |
| Dec 2025 | $132.1M | (5.64%) |
| Sep 2025 | $140.0M | 6.22% |
| 42 more quarters | Free account |
Against its own ten years
Low $95.6M
High $661.8M
Ten-year median
$346.2M
Current reading's percentile
73
Net income against peers
| Company | Net income |
|---|---|
| MDLN Medline Inc. compare | $1.9B |
| RMD ResMed Inc. compare | $1.5B |
| SOLV Solventum Corporation compare | $1.4B |
| BDX Becton, Dickinson and Company compare | $942.0M |
| ALC Alcon compare | $643.0M |
| COO The Cooper Companies, Inc. compare | $570.3M |
| WST West Pharmaceutical Services, Inc. | $564.9M |
| RGEN Repligen Corporation compare | $41.5M |
| BAX Baxter International Inc. compare | −$1.1B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on WST
- Revenue
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement